Abstract: A display substrate and a display apparatus. The display apparatus comprises a base substrate and, disposed on the base substrate, a plurality of light-emitting elements and a pixel defining pattern. The light-emitting elements comprise a light-emitting functional layer, a first electrode and a second electrode; the pixel defining pattern comprises a plurality of openings and a defining part surrounding the plurality of openings, and the light-emitting elements are at least partially located in the openings.

Abstract: A display panel includes a first subpixel region configured to emit light of a first color, a second subpixel region configured to emit light of a second color, and a third subpixel region configured to emit light of a third color. The display panel includes a first light-emitting diode including a first light emitting layer, a second light emitting diode including a second light emitting layer, and a third light-emitting diode including a third light emitting layer. The second light emitting layer and the third light emitting layer are spaced apart from each other. At least a first portion of the first light emitting layer and the third light emitting layer are parts of a unitary layer continuously extending from the third subpixel region to at least a first portion of the first subpixel region. The third subpixel region is smaller than the second subpixel region.

Abstract: Display substrate, manufacturing method thereof and display device are provided. The display substrate includes: light-emitting substrate including light-emitting device, switch element and encapsulation layer; color conversion layer including separation bank, color conversion pattern and leveling layer, the separation bank defining first openings corresponding to pixels, including light-transmitting bank and light-shielding bank patterns, the light-transmitting bank pattern has grooves in which the light-shielding bank pattern is filled, the color conversion pattern is disposed in the first openings, the leveling layer is at least partially filled in the first opening to fill first step for forming flat surface away from the substrate; a color filtering layer including light-shielding and color filtering patterns, the light-shielding pattern defining second openings corresponding to the first openings in which the color filtering pattern is disposed in.

Abstract: Provided is a color conversion substrate. The color conversion substrate includes: a base substrate; a reflective isolation portion on a side of the base substrate, a plurality of pixel apertures being defined in the reflective isolation portion, wherein the plurality of pixel apertures include a plurality of first-type pixel apertures arranged in arrays and a plurality of second-type pixel apertures arranged in arrays, and a plurality of lines of the first-type pixel apertures and a plurality of lines of the second-type pixel apertures are alternately arranged; and a color conversion layer, including a first color conversion pattern, a second color conversion pattern, and a transmission pattern, wherein the first color conversion pattern and the transmission pattern are disposed in different first-type pixel apertures, and the second color conversion pattern is disposed in the plurality of second-type pixel apertures.

Abstract: A cyclic dinucleotide analogue, a pharmaceutical composition thereof, and application. A cyclic dinucleotide analogue (I), an isomer thereof, a prodrug, a stable isotope derivative, or a pharmaceutically acceptable salt has the following structure. The cyclic dinucleotide analogue can be used as a regulator of a stimulator of interferon genes (STING) and a related signal path thereof, and can effectively treat and/or relieve multiple types of diseases, including but not limited to malignant tumors, inflammations, autoimmune diseases, and infectious diseases. In addition, the STING regulator can also be used as a vaccine adjuvant.

Abstract: A KRAS inhibitor compound represented by formula (I), and an isomer or a pharmaceutically acceptable salt thereof. The compound represented by formula (I) and the composition thereof can effectively treat diseases related to KRAS mutation.

Abstract: A cyclic dinucleotide analogue, a pharmaceutical composition thereof, and application. A cyclic dinucleotide analogue (I), an isomer thereof, a prodrug, a stable isotope derivative, or a pharmaceutically acceptable salt has the following structure. The cyclic dinucleotide analogue can be used as a regulator of a stimulator of interferon genes (STING) and a related signal path thereof, and can effectively treat and/or relieve multiple types of diseases, including but not limited to malignant tumors, inflammations, autoimmune diseases, and infectious diseases. In addition, the STING regulator can also be used as a vaccine adjuvant.

Abstract: The present invention relates to a cyano-substituted heteroarylpyrimidinone derivative represented by formula (I), a preparation method therefor and a use thereof as a therapeutic agent, in particular a use as an acetyl-CoA carboxylase (ACC) inhibitor, and the definition of each substituent in formula (I) is the same as the definition in the description.

Abstract: The present invention relates to a cyano-substituted heteroarylpyrimidinone derivative represented by formula (I), a preparation method therefor and a use thereof as a therapeutic agent, in particular a use as an acetyl-CoA carboxylase (ACC) inhibitor, and the definition of each substituent in formula (I) is the same as the definition in the description.